• peak
  • The increment in serum insulin levels after the 5-min s.c. infusion reached a peak of 62 +/- 9.5 mU/L at 45 min, and the rate of elevation of insulin levels closely approximated the normal insulin response to a 50-g, 500 kcal mixed meal. (garvan.org.au)
  • The increment in serum insulin levels with the 30-min s.c. infusion reached a peak of 41 +/- 1.4 mU/L at 75 min. (garvan.org.au)
  • clinical
  • Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failur. (bio-medicine.org)
  • SAN MATEO, Calif., Oct. 18, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed patient dosing of an open-label Phase I clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. (bio-medicine.org)
  • Control
  • The only significant side effect observed during these years was the development of subcutaneous nodules with occasional insufficient control of calcemia. (biomedsearch.com)